Theraclion's Strategy Is in Place for 2021 Despite the Impact of Covid-19 on Sales Revenues For 2020
19 Janvier 2021 - 06:30PM
Business Wire
Regulatory News:
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE,
PEA-PME eligible), an innovative company specializing in the
development of medical equipment for echotherapy treatment, notably
for varicose veins, today announces its sales revenues for the
year 2020 and roll-out strategy for 2021.
Roll-out strategy 2021
SONOVEIN S, the last generation of SONOVEIN® systems (CE marking
obtained in Oct. 2020), makes SONOVEIN a strong alternative in
treatment of varicose veins. It allows faster non-surgical
treatment on an ambulatory basis without the need for anaestesia.
Since October the company has made significant progress with their
roll-out strategy. For 2021, it plans to further expand business
development in new territories including Asia. Theraclion will also
significantly increase SONOVEIN S installations at new key opinion
leader sites. These international experts show strong interest in
this distruptive technology. Once equipped, their centers of
excellence are the relay of the technology to the rest of the
market. SONOVEIN S will then gradually become the gold standard
treatment for patients with chronic vein insufficiency.
Furthermore, Professor Dr. Mark Whiteley, renowned UK Venous
Surgeon, presented excellent 6 months efficacy results at the
American Vein & Lymphatic Society (AVLS). SONOVEIN S has been
installed at his clinics in addition to the already existing
installation at Melk, Austria. The company raised €3.0 million from
investors and secured €1.5 million in PGE loan from BPI France and
CIC . This allow the company to move forward on the commercial
roll-out of SONOVEIN S.
2020 activity impacted by the global health crisis
Theraclion SA achieved a turnover of €744K in 2020, a decrease
of 73% compared to 2019. Recurring revenue consisting of the sale
of consumables and services reached €467 K growing 8%. One system
was sold in 2020 against eleven in 2019.
Echotherapy treatments, not being qualified as an urgent
procedure, were suspended most of the year in most countries due to
COVID 19. Despite the lock down, the clinical trial for SONOVEIN S
could be successfully completed and used post-CE marking in
standard clinical practice in London.
Travel limitations, as well as restrictions on gatherings
reduced severly commercial contacts and most hospitals were forced
to halt focus on new equipment to concentrate on COVID 19 only.
However online discussions and pipeline building has continued
online. Whilst the impact on Theraclion’s business, which is mostly
international, was significant, preparations for 2021 business
development continued.
However, the company regained its business development and
accelerated its efforts with potential buyers of the technology in
Q3 and Q4. A gradual resumption of treatments and an increase in
orders for consumables and systems also took place in the second
half of the 2020 year.
Annual revenue/K€
2020
2019
Variation
Sales of systems
277
2 352
-88%
Sales of consumables
315
241
+31%
Sales of services
152
191
-20%
Total sales Theraclion SA
744
2 784
-73%
Out of which Thyroid and
Breast
592
2111
-72%
Out of which varicose veins
152
673
-77%
Out of which recurring sales
(1)
467
432
+8%
(1) Recurring sales = Sales of consumables + sales of
services
Despite COVID 19 lock–down, we have treated more varicose veins
than last year (+142% veins consumables sale revenues) despite
severe lock-downs and restrictions on none lifesaving surgical
procedures in Western Europe. System sale was difficult due to
hospital budget re-allocation to critical care. We are still in the
process of executing the sales of 3 systems which were delayed by
the pandemy.
About Theraclion
Theraclion has developed an innovative high-tech echotherapy
solution using High Intensity Focused Ultrasound for the treatment
of varicose veins, SONOVEIN®. The treatment solution, which
obtained CE marking in April 2019, is based on the leading-edge
echotherapy treatment expertise developed over years by Theraclion
for non-invasive ablation of breast fibroadenomas and thyroid
nodules using its ECHOPULSE® solution. Further improvements to the
ECHOPULSE technology are the foundation for SONOVEIN to provide the
only non-invasive ablation therapy for varicose veins. This
procedure allows for a treatment without a catheter, chemical
injection, or incision. An operating room is not necessary, and the
treatment can be performed at a doctor’s office, in a clinic, as
well as in a hospital. Venous pathology is widespread worldwide and
generates around 5 million treatment procedures per year, according
to Millennium research Varicose Vein Device Market Study 2015.
Theraclion's technological solutions are based on hightech
ultrasound medical imaging devices that are precise and easy to use
for practitioners.
Located in Malakoff, near Paris, Theraclion brings together a
team of 25 people, more than half of whom are dedicated to R&D
and clinical trials.
For more information, please visit the Theraclion website:
www.theraclion.com and the patient site:
https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119005855/en/
Theraclion David Auregan Chief Finance Officer
david.auregan@theraclion.com
Anja Kleber VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024